Modified STING-activating cyclic dinucleotide derivatives significantly enhance the anti-tumor activity of therapeutic vaccines

Documenti analoghi

• Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants
  di: Dubensky, Thomas W., et al.
  Pubblicazione: (2013)
• Direct activation of STING in the tumor microenvironment with synthetic cyclic dinucleotide derivatives leads to potent and systemic tumor-specific immunity
  di: Corrales, Leticia, et al.
  Pubblicazione: (2014)
• Cyclic dinucleotides (CDNs) reversed T cells tolerance in anti-tumor immunotherapy
  di: Fu, Juan, et al.
  Pubblicazione: (2015)
• TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
  di: Francica, Brian J., et al.
  Pubblicazione: (2018)
• STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
  di: Fu, Juan, et al.
  Pubblicazione: (2015)